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Introduction
Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase 
[HMGCR] inhibitors), since their introduction more than 
20 years ago, have been one of the most widely prescribed 
medications used to treat atherosclerotic disease. Treatment 
with statins has effectively reduced morbidity and mortality 
for both cardiovascular and cerebral vascular diseases. 
Millions of prescriptions are written annually for this class of 
medication. Given this number of prescriptions written, it is 
of major importance to closely observe patients for adverse 
and even life-threatening side effects. Herein, we examine a 
rare but serious case of statin-associated autoimmune myo-
pathy (SAM).
Case Report
A 70-year-old man presented to the emergency department 
after sustaining a fall at home. The patient was admitted to the 
intensive care unit for a large subdural hematoma and required 
respiratory support with mechanical ventilation. Prior to his 
fall, the patient had noticed increasing pain and weakness 
located bilaterally in the proximal shoulder and hip girdle 
region, but no other focal symptoms. His home medications 
for the past two years included, atorvastatin 40 mg once daily 
and aspirin 81 mg once daily without adverse effects during 
that time.
His creatine kinase (CK) on presentation was found to be 
12 300 IU/L, the statin was discontinued. Despite this, the CK 
remained persistently elevated, without clinical evidence of 
improvement in the patient’s weakness. The patient was evalu-
ated by several specialists and underwent with extensive testing 
for neuromyopathies including autoimmune, paraneoplastic, 
and chronic viral infection—all with negative findings. Tests 
for autoantibodies were negative, including antinuclear anti-
body, rheumatoid factor, anti-Ro/SSA, anti-La/SSB, and anti-
Jo-1. The myositis panel was negative for PL-7 Ab, PL-12Ab, 
EJ Ab, OJ Ab, SRP Ab, Mi-2 Ab, and Ku Ab. The patient was 
also seronegative for HIV and hepatitis A, B, and C infections. 
A computerized computed tomographic (CT) scan of the 
chest, abdomen, and pelvis with intravenous (IV) and oral 
(PO) contrast was unremarkable for malignancy. Nerve con-
duction study demonstrated no evidence of neuropathy. 
However, needle electromyography demonstrated features 
consistent with an active myopathic process with abnormal 
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spontaneous activity. Prior to the initiation of corticosteroid 
and rituximab therapy, a muscle biopsy was performed and 
revealed a pauci-immune necrotizing myopathy with the 
absence of macrophage infiltration, inclusion bodies and vascu-
lar abnormalities (Figure 1). Serologic testing also revealed 
HMGCR autoantibodies consistent with an autoimmune pro-
cess and established the diagnosis of statin -associated autoim-
mune myopathy. 
Initially, the patient was treated with high-dose corticoster-
oids (IV methylprednisolone, 40 mg every 8hr) but required the 
addition of rituximab (IV 1000 mg for  3 doses) when no clini-
cal improvement was seen. Of note, it was difficult to assess 
and quantify the patient’s strength, given his dependence on 
mechanical ventilation and sedation. However, the patient’s 
CK did improve to 1500 IU/L. While continuing rituximab a 
corticosteroid taper was attempted; however, the CK relapsed 
toward 9000 IU/L, and he subsequently required an increase in 
corticosteroid dosing (Figure 2). 
The patient had mild clinical improvement with the treat-
ments as described above following the diagnosis of SAM, and 
was liberated from the ventilator. Unfortunately, he once again 
developed respiratory distress and ultimately required a trache-
ostomy and return to ventilator support. After 2 months of his 
initial presentation, he was discharged to a long-term acute 
care facility on a drug regime consisting of a high-dose corti-
costeroid, rituximab, and methotrexate. Eventually, corticoster-
oids were successfully tapered but rituximab and methotrexate 
were continued, given incomplete remission. Unfortunately, he 
died 3 months after being transferred due to ventilator-associ-
ated pneumonia.
Discussion
Despite being one of the most commonly prescribed medica-
tions, the latest guidelines from the American College of 
Cardiology and the American Heart Association advocate for 
increase use; the number of prescriptions for statins is expected 
to increase substantially. Per the Centers for Disease Control 
and Prevention, 36.7% of US adults, 78.1 million people aged 
21 years or older, are eligible for statin medication; however, 
approximately 40 million people are actually taking statins.1 
Statins have been shown to have an acceptable side effect pro-
file and have been found to be generally safe in their indicated 
patient population. Studies have shown that a wide range 
(5%-20%) of patients discontinue statin therapy due to intol-
erance of side effects.2,3 Muscle complaints are the most well-
known and common side effect of statins and can range from 
asymptomatic with elevation in CK, mild elevation of CK 
with myalgia, and profound elevation of CK with frank rhab-
domyolysis. In initial clinical trials of statins, myalgia and/or 
myopathic symptoms (muscle pain without elevation of mus-
cle enzymes) were not identified as common adverse events, 
with only 1% to 5% of participants reporting muscle-related 
side effects. However, subsequent observational studies have 
estimated a much higher incidence of muscle complaints, 
ranging from 9% to 20%. This illustrates the point that the 
true side effect profile may not be captured by clinical trials, 
possibly given their restrictive inclusion criteria.4
Myopathy or myositis is generally defined as muscle pain, 
cramps, soreness, and/or concomitant elevation in CK. It has 
been estimated to occur in 5 patients per 100 000 person-years, 
and the incidence of myopathy generally increases with higher 
dosage of statins.5
Rhabdomyolysis is defined as a marked increase in CK 
levels, more than 10 times the upper limit of normal, which 
results from massive destruction of muscle fibers and the cor-
responding release of their contents into the bloodstream. It 
can induce renal failure and death; however, the rate of occur-
rence is low, that is, ~1/100 000 or roughly 324 cases per year.6 
A dose-response relationship is also observed in the incidence 
of rhabdomyolysis.
Recently, a rare but unique entity has received increasing 
attention called statin-associated autoimmune myopathy; the 
clinical spectrum and presentation of statin-induced myotox-
icity consist of asymptomatic elevation of CK, muscle pain or 
weakness, biopsy-proven myositis, and/or rhabdomyolysis 
with evidence of muscle-cell necrosis on biopsy and the pres-
ence of autoantibodies to HMGCR.7 The distinct histologic 
profile consists of profound necrotic, degenerating, or regen-
erating muscle fibers undergoing phagocytosis with mac-
rophage predominance.8 The reported sensitivity and 
specificity of positive anti-HMGCR for autoimmune statin 
myopathy are 94.4% and 99.3%, respectively.9
Although no prospective clinical trials have yet been com-
pleted to allow for evidence-based guidelines for diagnosis or 
treatment of SAM, the following approach has been advised. 
Initial workup for patients with current or past statin usage 
who present with proximal muscle weakness and/or muscle 
pain begins with obtaining CK levels. CK levels ⩾10 times 
the upper limit of normal are suggestive of SAM, whereas lev-
els below this threshold should lead the clinician toward 
investigation of other causes of weakness and muscle. For 
Figure 1. Severe myofiber atrophy with necrosis and myocytolysis not 
associated with endomysial inflammation. Frozen section (hematoxylin-eosin).
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patients with significantly elevated CK, discontinuation of the 
statin is indicated, allowing up to 8 weeks for observation of 
symptoms before repeating CK levels (sooner if symptoms 
progress). If CK levels remain ⩾10 times the upper limit of 
normal 8 weeks after discontinuation of the statin or if symp-
toms progress after statin discontinuation, the patient should 
be tested for anti-HMG-CoA reductase autoantibody. A pos-
itive test for anti-HMG-CoA reductase autoantibody yields 
presumptive diagnosis of SAM.7
Statin-associated autoimmune myopathy may occur any-
time and even long after initial exposure or statin cessation. 
This is evidenced by elevation of CK and relapse in patients 
despite discontinuation of the statin. This may occur even 
while on corticosteroid or immunomodulatory therapy. 
There are case reports of patients off statin therapy for more 
than 6 months and then develop the classic characteristic 
clinical features of SAM.9 Patients can have marked weak-
ness, and electrodiagnostic evidence of an active myopathic 
process and this can be seen up to 11 years after statin cessa-
tion. A case series done by Ramanathan et al demonstrated 
that patients required multiple immunosuppressive agents to 
achieve clinical remission, and almost all of those that 
relapsed seemed to be related to de-escalation of high-dose 
corticosteroids.10 Therefore, suspicion and early recognition 
of this diagnosis, use of multiple immunomodulatory agents, 
and a cautious approach to corticosteroids taper are war-
ranted. At this time, there are no prospective trials with 
long-term follow-up evaluating the duration and course of 
this myopathic process. There has yet to be an optimal defin-
itive induction, maintenance, and remission therapy. 
Recommendations for treatment of SAM are as follows: first 
discontinue statin and observe symptoms. If symptoms 
remain unchanged or clinically worsen, begin initial therapy 
with oral prednisone. In cases of severe weakness, the clini-
cian may consider a second agent at onset of treatment with 
prednisone, such as methotrexate, azathioprine, or mycophe-
nolate mofetil. Rituximab or IVIG may be considered after 8 
to 12 weeks if no response with prednisone with or without a 
second agent or sooner in more severe presentations of the 
condition. IVIG is typically reserved for severe or refractory 
cases but has been described to be effective as a first-line 
agent in patients. In a case series, three patients with SAM 
and underlying diabetes mellitus were treated with IVIG as 
monotherapy after declining corticosteroid treatment due to 
potential side effects—partial to full recovery of strength was 
demonstrated. The combination of prednisone, IVIG, and a 
steroid-sparing agent was used in nearly one-half of cases 
described in literature. Treatment of SAM with triple ther-
apy has been recommended. There is also evidence of using 
IVIG as the sole treatment as depicted by Dr. Mammen in 
his review article on SAM in the New England Journal of 
Medicine.11 IVIG has been suggested to be first line therapy 
in severe cases, especially in those who present with an 
aggressive course.12
Figure 2. CK trend over the course of days including when particular treatments were implemented.
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It is hypothesized that statins may increase the expression of 
HMGCR autoantibody in regenerating muscle fibers. This self-
antigen would perpetuate an immune response. This may explain 
why patients have a propensity to relapse up on de-escalation of 
immunosuppression or immunomodulatory therapy.13 This is 
further evidenced in a recent study which demonstrated patients 
responded well to immunosuppressive treatment, but serum lev-
els of the anti-HMGCR antibody remained high and did not 
correlate with disease activity.14
Conclusions
Statin-associated autoimmune myopathy has a unique clini-
cal, histologic, and therapeutic profile that separates it from 
other inflammatory myopathies. With the new 
Atherosclerotic Cardiovascular Disease (ASCVD) risk cal-
culator in place and improving access to health care, we 
expect an increasing use of statin medications. With the ben-
efits of statins with regard to reducing risk of both cardiovas-
cular and cerebrovascular events far outweigh risk and 
potential adverse effects of these medications; it is crucial for 
providers to remain aware of possible and even rare side 
effects of these medications and how to test for them. Statin-
associated autoimmune myopathy has been described as an 
exceedingly rare complication of statin use and is often 
underrecognized in clinical practice; we urge providers to 
educate patients to alert their physicians if any signs or 
symptoms of serious myopathy occur.
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